Serum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty liver diseaseErina Kumagai, Tatsuya Kanto, Yohei Mano et al.|Scientific Reports|2016Cited by 105
Interleukin-34 as a fibroblast-derived marker of liver fibrosis in patients with non-alcoholic fatty liver diseaseHirotaka Shoji, Tatsuya Kanto, Sachiyo Yoshio et al.|Scientific Reports|2016Cited by 64
Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular CarcinomaMakoto Chuma, Shin Maeda, Shuitirou Iwasaki et al.|Cancers|2020Cited by 54
Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: A multicenter analysisMakoto Chuma, Shin Maeda, Haruki Uojima et al.|Hepatology Research|2020Cited by 38
Relationship between response to lusutrombopag and splenic volumeHaruki Uojima, Wasaburo Koizumi, Yoshitaka Arase et al.|World Journal of Gastroenterology|2018Cited by 25